Clinical trial
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
NCT01868997 · Amgen, Industry · Completed
Key facts
| NCT number | NCT01868997 |
|---|---|
| Title | Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease |
| Official title | A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED) |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy |
| Intervention type | Drug |
| Interventions | teprotumumab, normal saline |
| Enrollment | 88 |
| Start date | Jul 1, 2013 |
| Primary completion | Mar 1, 2016 |
| Completion | Feb 22, 2017 |
| First posted | Jun 5, 2013 |
| Last update posted | Dec 17, 2024 |
| Countries | Germany, Italy, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: